Retatrutide is an investigational triple-receptor agonist peptide (targets GLP-1, GIP, and glucagon receptors) under development for obesity and type 2 diabetes[1][2]. Phase 2 trials demonstrated remarkable weight-loss efficacy, with patients losing up to 24% of body weight at 48 weeks on higher doses[3][4]. This educational protocol presents a once-weekly subcutaneous approach with gradual titration to minimize gastrointestinal side effects.
GLP3 RETA 10MG
Original price was: $80.00.$60.00Current price is: $60.00.
GLP3 RETA is an advanced multi-agonist peptide designed to interact with GLP-1, GIP, and glucagon receptors, offering broad utility for controlled laboratory research models
Availability: 27 in stock
Reviews
There are no reviews yet.